Despite the remarkable achievements of anti-HER2 monoclonal antibody therapy, drug resistance and side effects caused by off-target effects on normal tissues remain major challenges in HER2+ breast cancer therapy. The gene discussed is ERBB2; the disease is breast carcinoma.